首页> 外文OA文献 >Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial

【2h】

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial

机译：氟尿嘧啶，同质素和环磷酰胺（FEC-75）随后是Paclitaxel Plus Trastuzumab与紫杉醇加曲妥珠单抗，然后是FEC-75加曲妥珠单抗作为HER2阳性乳腺癌患者的Neoadjuvant治疗（Z1041）：随机，受控，第3阶段试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Aman U Buzdar; Vera J Suman; Funda Meric-Bernstam; A Marilyn Leitch; Matthew J Ellis; Judy C Boughey; Gary Unzeitig; Melanie Royce; Linda M McCall; Michael S Ewer; Kelly K Hunt;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): A randomised, controlled, phase 3 trial [J] . BuzdarA.U., SumanV.J., Meric-BernstamF., The lancet oncology . 2013,第13期

机译：氟尿嘧啶，表柔比星和环磷酰胺（FEC-75）+紫杉醇+曲妥珠单抗vs紫杉醇+曲妥珠单抗+ FEC-75 +曲妥珠单抗作为HER2阳性乳腺癌（Z1041）患者的新辅助治疗：一项随机，对照，3期试验
2. Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial [J] . Tokunaga Shinya, Takashima Tsutomu, Kashiwagi Shinichiro, Anticancer Research: International Journal of Cancer Research and Treatment . 2019,第4期

机译：Neoadjuvant化疗用Nab-PACLitaxel Plus Trastuzumab，其次是5-氟尿嘧啶/同性全/环磷酰胺，用于HER2-阳性可操作的乳腺癌：多中心II期试验
3. Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer [J] . Foldi Julia, Mougalian Sarah, Silber Andrea, Breast cancer research and treatment. . 2018,第2期

机译：单臂，新辅助，Pertuzumab和Trastuzumab的II期试验，伴随着每周紫杉醇，然后均为5-氟尿嘧啶，表皮酰胺和环磷酰胺（FEC），用于阶段I-III Her2阳性乳腺癌
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Fluorouracil epirubicin and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised controlled phase 3 trial [O] . Aman U Buzdar, Vera J Suman, Funda Meric-Bernstam, -1

机译：氟尿嘧啶表柔比星和环磷酰胺（FEC-75）+紫杉醇+曲妥珠单抗vs紫杉醇+曲妥珠单抗+ FEC-75 +曲妥珠单抗作为HER2阳性乳腺癌（Z1041）患者的新辅助治疗：一项随机对照3期试验
7. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5 [O] . John W. Smith, Marc E. Buyse, Priya Rastogi, 2017

机译：环磷酰胺蛋白与环磷酰胺，其次是多西紫杉醇与Trastuzumab和Bevacizumab为Neoadjuvant治疗，用于Her2阳性局部晚期乳腺癌，或作为HER2阳性病理阶段III乳腺癌的辅助治疗：NSABP基金会研究组的II期试验，FB-5

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial

著录项

相似文献

相关主题

期刊订阅